FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196996910> ?p ?o ?g. }

• W3196996910 abstract "ABSTRACT Increases in bone mineral density (BMD) with osteoporosis treatment are associated with reduced fracture risk. Increasing BMD is therefore a goal of osteoporosis therapy. Here, we compare the probability of achieving a T ‐score of > −2.5 over 3 years at the total hip (TH) or lumbar spine (LS) in women with osteoporosis, ≥55 years of age, after the following treatment sequences: 1 year romosozumab followed by 2 years denosumab (FRAME and FRAME extension trials), 1 year romosozumab followed by 2 years alendronate, or alendronate‐only for 3 years (ARCH trial). Probabilities of attaining the BMD target within 1 year of treatment were also determined. At both skeletal sites, in women with a baseline T score ≥ −2.7, there was >50% probability of achieving the BMD target with any 3‐year regimen. The probability of achieving the target BMD in those with a baseline TH T score equal to −3.0 was 61% with romosozumab/denosumab, 38% with romosozumab/alendronate, and 9% with alendronate. In those with a baseline LS T score equal to −3.0, the probability of achieving a T ‐score > −2.5 was 93% with romosozumab/denosumab, 81% with romosozumab/alendronate, and 55% with alendronate. With 1 year of treatment, in patients with a baseline TH T ‐score equal to −2.7, the probability of reaching the target T score with romosozumab was 71% to 78% and 38% with alendronate. For patients with an initial LS T ‐score equal to −3.0, the probability of achieving the target T ‐score over 1 year was 85% to 86% with romosozumab and 25% for alendronate. Our findings suggest baseline BMD and the probability of achieving BMD T ‐score goals are factors to consider when selecting initial treatment for patients with osteoporosis. As baseline T ‐score falls below −2.7 (TH) and −3.0 (LS), alendronate has <50% likelihood of achieving a BMD goal above osteoporosis range, whereas these probabilities remain relatively high for regimens beginning with romosozumab. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research." @default.
• W3196996910 created "2021-09-13" @default.
• W3196996910 creator A5005830135 @default.
• W3196996910 creator A5008684739 @default.
• W3196996910 creator A5009972236 @default.
• W3196996910 creator A5010199500 @default.
• W3196996910 creator A5011735451 @default.
• W3196996910 creator A5024193923 @default.
• W3196996910 creator A5028056767 @default.
• W3196996910 creator A5044875947 @default.
• W3196996910 creator A5049735506 @default.
• W3196996910 creator A5065694314 @default.
• W3196996910 creator A5083518845 @default.
• W3196996910 creator A5083801035 @default.
• W3196996910 date "2021-10-06" @default.
• W3196996910 modified "2023-10-07" @default.
• W3196996910 title "Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals" @default.
• W3196996910 cites W1847281587 @default.
• W3196996910 cites W1990771263 @default.
• W3196996910 cites W2040386786 @default.
• W3196996910 cites W2096627331 @default.
• W3196996910 cites W2112363729 @default.
• W3196996910 cites W2335178464 @default.
• W3196996910 cites W2516614130 @default.
• W3196996910 cites W2520995084 @default.
• W3196996910 cites W2553677537 @default.
• W3196996910 cites W2605743908 @default.
• W3196996910 cites W2754720807 @default.
• W3196996910 cites W2767671304 @default.
• W3196996910 cites W2770338318 @default.
• W3196996910 cites W2793982131 @default.
• W3196996910 cites W2795290522 @default.
• W3196996910 cites W2797988192 @default.
• W3196996910 cites W2912416377 @default.
• W3196996910 cites W2935325905 @default.
• W3196996910 cites W3006754541 @default.
• W3196996910 cites W3012208209 @default.
• W3196996910 cites W3026845498 @default.
• W3196996910 cites W3040350801 @default.
• W3196996910 cites W3044275622 @default.
• W3196996910 cites W3047892256 @default.
• W3196996910 cites W3091952755 @default.
• W3196996910 cites W4210365181 @default.
• W3196996910 cites W4236641936 @default.
• W3196996910 cites W4253165656 @default.
• W3196996910 doi "https://doi.org/10.1002/jbm4.10546" @default.
• W3196996910 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8567484" @default.
• W3196996910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34761149" @default.
• W3196996910 hasPublicationYear "2021" @default.
• W3196996910 type Work @default.
• W3196996910 sameAs 3196996910 @default.
• W3196996910 citedByCount "1" @default.
• W3196996910 countsByYear W31969969102023 @default.
• W3196996910 crossrefType "journal-article" @default.
• W3196996910 hasAuthorship W3196996910A5005830135 @default.
• W3196996910 hasAuthorship W3196996910A5008684739 @default.
• W3196996910 hasAuthorship W3196996910A5009972236 @default.
• W3196996910 hasAuthorship W3196996910A5010199500 @default.
• W3196996910 hasAuthorship W3196996910A5011735451 @default.
• W3196996910 hasAuthorship W3196996910A5024193923 @default.
• W3196996910 hasAuthorship W3196996910A5028056767 @default.
• W3196996910 hasAuthorship W3196996910A5044875947 @default.
• W3196996910 hasAuthorship W3196996910A5049735506 @default.
• W3196996910 hasAuthorship W3196996910A5065694314 @default.
• W3196996910 hasAuthorship W3196996910A5083518845 @default.
• W3196996910 hasAuthorship W3196996910A5083801035 @default.
• W3196996910 hasBestOaLocation W31969969101 @default.
• W3196996910 hasConcept C126322002 @default.
• W3196996910 hasConcept C2776286101 @default.
• W3196996910 hasConcept C2776541429 @default.
• W3196996910 hasConcept C2776886416 @default.
• W3196996910 hasConcept C2777525943 @default.
• W3196996910 hasConcept C2994343686 @default.
• W3196996910 hasConcept C71924100 @default.
• W3196996910 hasConceptScore W3196996910C126322002 @default.
• W3196996910 hasConceptScore W3196996910C2776286101 @default.
• W3196996910 hasConceptScore W3196996910C2776541429 @default.
• W3196996910 hasConceptScore W3196996910C2776886416 @default.
• W3196996910 hasConceptScore W3196996910C2777525943 @default.
• W3196996910 hasConceptScore W3196996910C2994343686 @default.
• W3196996910 hasConceptScore W3196996910C71924100 @default.
• W3196996910 hasFunder F4320307105 @default.
• W3196996910 hasFunder F4320337846 @default.
• W3196996910 hasIssue "11" @default.
• W3196996910 hasLocation W31969969101 @default.
• W3196996910 hasLocation W31969969102 @default.
• W3196996910 hasLocation W31969969103 @default.
• W3196996910 hasLocation W31969969104 @default.
• W3196996910 hasLocation W31969969105 @default.
• W3196996910 hasLocation W31969969106 @default.
• W3196996910 hasOpenAccess W3196996910 @default.
• W3196996910 hasPrimaryLocation W31969969101 @default.
• W3196996910 hasRelatedWork W1909034630 @default.
• W3196996910 hasRelatedWork W2016689947 @default.
• W3196996910 hasRelatedWork W2081825967 @default.
• W3196996910 hasRelatedWork W2124617132 @default.
• W3196996910 hasRelatedWork W2287839548 @default.
• W3196996910 hasRelatedWork W2408089570 @default.
• W3196996910 hasRelatedWork W2606358690 @default.
• W3196996910 hasRelatedWork W3162303886 @default.

• next